Get the Stockscreener App
0.0003
50.00%
0.000100
Effector Therapeutics Inc stock is traded at $0.0003, with a volume of 112.14K.
It is up +50.00% in the last 24 hours and up +50.00% over the past month.
See More
Previous Close:
$0.0002
Open:
$0.0003
24h Volume:
112.14K
Relative Volume:
53.81
Market Cap:
$N/A
Revenue:
$675.00K
Net Income/Loss:
$-34.63M
P/E Ratio:
-0.000023
EPS:
-13.3158
Net Cash Flow:
$-29.28M
1W Performance:
+50.00%
1M Performance:
+50.00%
6M Performance:
+50.00%
1Y Performance:
+50.00%
1-Day Range:
$0.0003
$0.0003
1-Week Range:
$0.0003
$0.0003
52-Week Range:
$0.0002
$0.0003
Effector Therapeutics Inc Stock (EFTR) Company Profile
Name
Effector Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare EFTR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EFTR
Effector Therapeutics Inc
|
0.0003 | 0 | 675.00K | -34.63M | -29.28M | -13.32 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Effector Therapeutics Inc Stock (EFTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-22 | Downgrade | Stifel | Buy → Hold |
| Nov-09-21 | Upgrade | Stifel | Hold → Buy |
| Oct-12-21 | Initiated | Credit Suisse | Outperform |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Sep-20-21 | Initiated | Stifel | Hold |
| Sep-13-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Effector Therapeutics Inc Stock (EFTR) Latest News
Better Therapeutics, Inc. (BTTX) Stock Price, News, Quote & History - Yahoo Finance
Effector Therapeutics Inc (NASDAQ: EFTR) Share Price, EFTR Stock News, EFTR Share Price & Updates - Kalkine
Enterprise value to revenue forward of eFFECTOR Therapeutics Inc – MUN:LWK - TradingView
Competitive Analysis: Leading Companies and New Entrants in - openPR.com
Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients - Clinical Leader
Attovia Therapeutics Appoints John W. Smither to Board of Directors - WBOC TV
If You Invested $1,000 in Ampio Pharma (AMPE) - Stock Titan
If You Invested $1,000 in Effector Therapeutics Inc (EFTR) - Stock Titan
If You Invested $1,000 in Innoveren Scientific Inc (IVRN) - Stock Titan
Price to earnings forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Price to book forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
Price to sales forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Price to sales forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
Enterprise value to EBITDA forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Enterprise value to EBITDA forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
eFFECTOR Therapeutics Inc Actuals & Estimates (OTC:EFTR) - TradingView
eFFECTOR Therapeutics Inc Actuals & Estimates (LS:A3ELKJ) - TradingView
PD-1 and PD-L1 Inhibitors Market Business Intelligence and Forecast Report 2026 to 2035 - openPR.com
What Does the Future Hold for Immune Effector Cell Therapies? - CancerNetwork
Calumet, IncCommon Stock (NQ: CLMT - FinancialContent
In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs - Science | AAAS
Bioinorganic Site-Specific Conjugation of Multi-Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions - Wiley Online Library
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Analysis of Key Market Segments Influencing the RNA Targeting Small Molecules Therapeutics Market - openPR.com
DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage - Nature
Insider ownership and executive pay at CERo Therapeutics (NASDAQ: CERO) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
eFFECTOR Therapeutics Inc (EFTRW) - Minichart
IOBTQ Stock Price and Chart — OTC:IOBTQ - TradingView
Entia Biosciences, Inc. (ERGO) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Celularity Inc. (CELU) stock price, news, quote and history - uk.finance.yahoo.com
Novartis to acquire Excellergy for up to $2 billion - National Today
Excellergy to be acquired by Novartis for up to USD 2 - GlobeNewswire
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - Yahoo Finance
Selective fluorination of Fc glycans enhances antibody-mediated effector functions - PNAS
EFTR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com
EFTR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CapEx per share of eFFECTOR Therapeutics Inc – MUN:LWK - TradingView
MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan
Reprogramming The Tumor Microenvironment Bringing A Metabolic Checkpoint Therapy Into The Clinic - Clinical Leader
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
ZIMCF Stock Price, News & Analysis - Stock Titan
Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection - Nature
Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium - OncLive
Indian American Premal Patel joins Elephas Biosciences as CMO - The American Bazaar
Working (Well) With Patient Advocates: The Sponsor POV - Clinical Leader
ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM - PR Newswire
Reaching Patients Where They Are: Moving CGT Care into the Community - HMP Global Learning Network
FACT's New Standards for Immune Effector Cells in the Community Clinical Setting Help Bring Cell Therapies Closer to Patients - Yahoo Finance
cells from effector T cells for cell therapy of inflammatory diseases - Science | AAAS
Effector Therapeutics Inc Stock (EFTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Cap:
|
Volume (24h):